Mood Stabilizers: Bipolar Treatment, Monitoring and Medication Review

Bipolar treatment can address an episode of mania, a depressive episode or prevention of future episodes. Those goals overlap but are not interchangeable. A medicine used to reduce future risk may continue when someone feels well, while a treatment introduced for an acute episode may later be reviewed. Ask which role applies to each item on your prescription. [1]

It is helpful to separate the purpose of treatment from the desired experience. Feeling less overwhelmed, sleeping regularly and returning to normal activities may be welcome changes. Feeling emotionally numb, excessively tired or unable to think clearly is a different concern and deserves discussion. A useful review should examine both the illness pattern and the quality of everyday life.

NICE recommends lithium as a first-line long-term medicine for bipolar disorder. Suitability depends on the person’s clinical history, preferences and ability to participate in monitoring. Lithium is not a medicine that can be safely managed by symptoms alone: the prescribed product and blood-test arrangements matter even during a stable period. [1]

The NHS describes a treatment record and alert card to support safe use. Ask who arranges blood levels, when the sample should be taken in relation to your dose and how results will be communicated. Keep information about the actual brand and formulation available, particularly during travel, emergency treatment or a change of pharmacy. Do not substitute products or double a missed dose independently. [2]

Kidney and thyroid function can be affected during lithium treatment. Illness, dehydration and sudden changes in salt intake can also matter. Speak to the team promptly when vomiting, diarrhea or poor fluid intake changes your usual routine. Over-the-counter medicines should be checked rather than assumed harmless because they do not require a prescription. [3]

New or worsening tremor, weakness, blurred vision, unusual drowsiness, confusion, difficulty speaking or significant digestive illness can indicate lithium toxicity. Suspected toxicity requires immediate medical help and no further lithium while emergency advice is obtained. Do not drive yourself or wait for the next routine blood test. This emergency response is different from a planned gradual reduction for someone who is otherwise well. [3]

Before treatment continues across services, ask which contact should be used during illness and whether an out-of-hours team can see the monitoring record. A written sick-day discussion is useful, but it should not become a homemade instruction to stop and restart lithium whenever you feel unwell. The actual symptoms and circumstances need clinical assessment.

Lamotrigine is used in epilepsy and bipolar care, including prevention of depressive episodes in appropriate treatment plans. It is not an immediate rescue medicine for a rapidly escalating mood episode. Treatment is introduced gradually, with the schedule influenced by other medicines. A person taking valproate may require different instructions from someone taking lamotrigine alone. [4]

A new rash needs prompt medical advice. Blisters, peeling skin, mouth or eye sores, fever or facial swelling can indicate a severe reaction requiring urgent assessment. Do not restart after an interruption at the former dose without checking with the prescriber. Bring the written introduction plan to a review and explain any doses missed rather than trying to reconstruct a different schedule yourself. [4]

Hormonal contraception can interact with lamotrigine, so starting, stopping or changing contraception should be discussed. Pregnancy and breastfeeding decisions also need individual advice. A medicine described as more suitable in one situation is not automatically risk-free in another. The plan should identify who coordinates psychiatric and reproductive care. [4]

Valproate is an umbrella term for related formulations with different licensed uses. The UK indications for semi-sodium valproate and other formulations are not identical. In bipolar care, its place depends on the treatment phase, previous response and the alternatives. The active ingredient alone is not enough to determine whether a particular prescription matches local authorization. [1]

Valproate carries important reproductive risks. UK safety requirements include specialist restrictions on starting treatment in people younger than fifty-five and pregnancy-prevention requirements for women and girls able to become pregnant. Advice for men includes discussion of fertility and possible risks around conception. These questions need specialist review; do not stop valproate independently because of a warning read online. [5]

Distinguish people starting treatment from people already taking it. The MHRA clarified that the two-specialist starting requirement is not an automatic requirement for every man already established on valproate. Ask which current rules apply to your circumstances rather than relying on an outdated summary. A planned pregnancy should be raised early enough for an informed discussion of options. [6]

Carbamazepine is an anticonvulsant with a role in some bipolar treatment plans, as well as epilepsy and particular pain conditions. Its interactions can affect other psychiatric medicines and hormonal contraception. Tablets, liquids and other formulations require their own instructions. A prescriber should review the complete regimen before adding or withdrawing another medicine. [7]

Report a rash with blisters or mouth sores, serious allergic symptoms, jaundice or other substantial deterioration promptly. Dizziness, tiredness and coordination problems can also interfere with driving and daily activity. Explain both the symptom and its practical impact, rather than assuming that a familiar medicine no longer needs review. [7]

The fact that a medicine treats seizures does not establish that it is an effective mood stabilizer for every bipolar presentation. The choice needs evidence for the particular condition and phase. Similarly, a medicine prescribed for nerve pain, migraine or anxiety should not be counted automatically as a replacement for a bipolar maintenance plan. [1]

Ask your clinician to explain why each medicine is included and what would lead to reassessment. When several products are used, record which is targeting mood, which is treating another condition and which was introduced temporarily. This avoids confusing the presence of many medicines with a coherent plan.

Monitoring is not identical across this group. Lithium requires blood-level and organ-function monitoring; valproate requires attention to blood counts and liver function; anticonvulsants and antipsychotics have their own additional checks. Weight, physical health and adverse effects should be reviewed alongside mood symptoms. Ask for the relevant schedule rather than copying another patient’s list of tests. [1]

Make responsibilities explicit. Who orders each test, who receives it and who tells you whether anything changes? What happens if you move, miss an appointment or are admitted elsewhere? A good monitoring plan remains understandable when you are tired or unwell. Keep the medicine list and follow-up information together.

Co-occurring substance use requires its own assessment. A medicine used for bipolar disorder should not be assumed to prevent alcohol or sedative withdrawal simply because it is also an anticonvulsant. Alcohol can affect alertness, hydration and interpretation of symptoms, and it can complicate particular medicines such as lithium or carbamazepine. Describe actual use and recent changes to the prescriber. [3] [7]

A coordinated plan should distinguish mood treatment, withdrawal management and continuing addiction care. Do not alter a mood stabilizer to compensate for drinking or use spare medicine to attempt a home detox. The alcohol withdrawal guide addresses those separate safety questions. Ask how the psychiatric and addiction teams will communicate about any change.

A planned change should consider the pattern of previous episodes, current stability, side effects and available support. NICE recommends gradual withdrawal of relevant bipolar medicines with monitoring, not an abrupt self-directed stop. A return of symptoms and a withdrawal reaction are different possibilities, and both may need assessment. Feeling well does not alone answer how long maintenance treatment should continue. [1]

Ask for the purpose of the change in writing and clarify what remains unchanged. Discuss a previous difficult stopping attempt, including timing and symptoms, without feeling that you must diagnose it yourself. The withdrawal-or-relapse guide helps organize observations, while the individual medicine profile explains product-specific precautions.

Before travel or a change of clinician, confirm the exact product, the supply needed and how monitoring will continue. Ask for advice about dosing times rather than improvising across time zones. Carry a current list showing the active ingredient, brand where relevant and the prescriber’s contact details. Record which professional will help if you become unwell away from home.

For a transfer of care, request the most recent results and the reason for the current regimen. Include previous adverse reactions and clinically important interruptions. Do not rely on a remembered tablet color to identify a medicine or assume that a similar-looking product is equivalent. The aim is a clear handover that another healthcare professional can use, without requiring you to reconstruct the entire treatment history during a stressful appointment.

Does a mood stabilizer prevent all emotions?

No treatment goal should be defined as removing normal feelings. Describe emotional blunting or difficulty thinking at review so the clinician can assess the experience and the treatment plan.

Can I stop because I am planning pregnancy?

Arrange specialist advice promptly, but do not independently stop a medicine needed to control bipolar disorder or epilepsy. The options and risks differ by product. [5]

Do I need monitoring when I feel stable?

Yes, when it is required for your medicine. Tests and clinical review remain part of safe continuing treatment rather than only a response to symptoms. [1]

1. NICE CG185: Bipolar disorder recommendations.
2. NHS: Taking lithium.
3. NHS: Lithium adverse effects and toxicity.
4. NHS: Lamotrigine.
5. MHRA: Valproate reproductive risks.
6. MHRA: Review requirements for men already taking valproate.
7. NHS: Carbamazepine.

Explore individual profiles and the review checklist in the A-Z directory.